A two-part study in Japanese patients with advanced or metastatic NSCL [non-small cell lung cancer]. Open-label phase I to assess the safety and tolerability of AZD2171 [cediranib] in combination with pac/carb [paclitaxel/carboplatin], then a phase II, randomised, double-blind study to assess the efficacy of AZD2171 alone and in combination with pac/carb

Trial Profile

A two-part study in Japanese patients with advanced or metastatic NSCL [non-small cell lung cancer]. Open-label phase I to assess the safety and tolerability of AZD2171 [cediranib] in combination with pac/carb [paclitaxel/carboplatin], then a phase II, randomised, double-blind study to assess the efficacy of AZD2171 alone and in combination with pac/carb

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 20 Dec 2016

At a glance

  • Drugs Carboplatin; Cediranib; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Dec 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 17 Jun 2009 Additional lead trial investigator Jane Robertson identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top